BIIB: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Net income	1,341,800	875,300	240,500	1,365,500
Depreciation and amortization	579,700	377,500	183,200	489,200
Impairment of intangible assets	3,500	3,500	-	20,200
Excess and obsolescence charges related to inventory	13,900	14,300	7,300	68,700
Amortization of acquired inventory step-up	165,400	103,900	51,400	185,100
Share-based compensation	231,200	155,900	81,000	216,100
Contingent consideration	28,400	22,800	9,600	23,800
Deferred income taxes	194,700	-59,100	-27,800	-99,700
(gain) loss on strategic investments	-33,700	-33,200	-40,900	-22,700
Gain on sale of priority review voucher, net	0	0	-	88,600
Other	-49,300	-16,000	-6,700	-95,100
Accounts receivable-Nonrelated Party	-74,900	170,500	181,000	-127,600
Accounts receivable-Related Party	11,800	-4,200	-70,400	15,900
Inventory	35,300	27,900	-62,000	207,400
Accrued expense and other current liabilities	-32,700	-318,700	-300,500	-84,200
Income tax assets and liabilities	-764,100	-534,700	69,100	62,100
Other changes in operating assets and liabilities, net	179,900	75,500	53,500	65,700
Net cash flow provided by (used in) operating activities	1,692,700	420,200	259,300	2,114,600
Purchases of property, plant and equipment	109,900	63,700	37,100	114,400
Proceeds from sales and maturities of marketable securities	-	-	-	0
Purchases of marketable securities	91,000	-	-	0
Acquisition of hi-bio, net of cash acquired	0	-	-	1,074,800
Proceeds from sale of equity interest in samsung bioepis	0	0	-	406,800
Proceeds from sale of priority review voucher	0	0	-	88,600
Acquisitions of intangible assets	15,300	10,000	10,000	179,100
Proceeds from sales of strategic investments	56,600	0	0	96,700
Other	-20,200	30,600	200	4,400
Net cash flow provided by (used in) investing activities	-139,400	-104,300	-47,300	-780,600
Payments related to issuance of stock for share-based compensation arrangements, net	13,000	18,200	24,300	34,800
Proceeds from borrowings	1,733,100	1,733,400	-	0
Repayments of borrowings	1,750,000	1,750,000	0	650,000
Net (distribution) contribution to noncontrolling interest	-	-	-	0
Cash paid for contingent consideration	141,300	-	-	-
Other	6,300	100	1,300	-6,600
Net cash flow provided by (used in) financing activities	-164,900	-34,700	-23,000	-691,400
Net increase (decrease) in cash and cash equivalents	1,388,400	281,200	189,000	642,600
Effect of exchange rate changes on cash	99,400	102,600	34,300	6,700
Cash and cash equivalents at beginning of period	2,375,000	2,375,000	2,375,000	1,049,900
Cash and cash equivalents at end of period	3,862,800	2,758,800	2,598,300	1,699,200

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

BIIB: the cashflow